Intercept’s $500M Plan to End Common Respiratory Infections Using AI

⏱ 8 min read · Last updated 2026-06-25

Intercept, a $500 million philanthropic initiative, held a symposium at Stripe in August that gathered roughly 40 leading scientists, pharma R&D leaders, biotech venture capitalists, and regulatory experts. Their conclusion: respiratory infections are not a fact of life. They are a tractable engineering problem hiding behind decades of underfunding. The initiative is now betting that two product categories, broad-spectrum preventatives and air-cleaning technologies, can slash the burden of colds, flu, and other respiratory viruses, and eventually eliminate them altogether.

Why It Matters

Routine respiratory illness is treated as a seasonal nuisance, but the cumulative cost told by the data is staggering. Healthy adults spend roughly 15 to 25 days each year, about 5% of their lives, sick with colds or flu. In 2021, researchers tallied 12.8 billion respiratory infections globally, the vast majority viral. Each year, more than 65 million of those progress to serious lower respiratory disease, and respiratory infections account for roughly 7% of all deaths from major causes in the United States. The economic toll is just as heavy: routine respiratory illness drives an estimated 1 to 1.5% of annual productivity losses, roughly $600 billion globally, or about 0.6% of global GDP, in non-pandemic years. Downstream health links are even more concerning. Children infected with human rhinovirus between birth and age three carry a 9.8x higher risk of asthma by age six in a high-risk cohort. A heart attack is 6.1x more likely in the seven days after an influenza infection. Severe influenza is associated with a 4.5 to 5x increase in dementia risk, while severe influenza and pneumonia together are linked to a 2.6 to 4.1x increase in Alzheimer’s risk. Maternal influenza during pregnancy has been associated with a 2.2 to 3x potential increase in schizophrenia risk for the infant.

What’s New / How It Works

Intercept is pursuing two complementary defenses. The first is broad-spectrum preventatives, or BSPs, drugs and vaccines that protect against rhinoviruses, influenza, coronaviruses, and other respiratory viruses simultaneously. The target: preventatives that block more than 75% of symptomatic infections, in as few doses as possible, through easy-to-administer modalities, with a credible path to roughly 60% uptake. That number mirrors the realistic ceiling of existing vaccine adoption, because pushing any single intervention to 100% is extremely difficult. Commercial fire sprinkler penetration sits at about 40% in the US as a benchmark.

The second category is air-cleaning technologies, or ACTs, such as advanced air filtration and far-UVC antimicrobial light, designed to scrub pathogens from high-density spaces like offices, schools, and public transit. On their own, even a near-perfect preventative cannot eliminate a virus with a basic reproduction number (R0) of 3.0 if uptake is only 60%; roughly 67% population protection is needed to push the effective reproduction number below 1. ACTs close that gap by reducing the virions circulating in shared indoor air. Deployed together at realistic levels, BSPs and ACTs can drive a virus’s effective reproduction number below the elimination threshold.

The scientific playbook for BSPs draws on five overlapping approaches:

• Adaptive immunity: Beyond broadly neutralizing antibodies, researchers are exploring CD8 T cells stationed at the site of infection that can stop a virus from establishing itself after exposure. The challenge is to work across diverse populations and account for population-level immune diversity.
• Direct-acting antivirals: New nucleic acid degrader platforms, including siRNA, unlock antiviral targets inside cells that are highly conserved across viruses. Broad-spectrum small molecules target conserved proteins like RNA polymerase or disrupt viral membranes.
• Innate immunity modulators: Engineered interferons and small molecule agonists of pathways like cGAS/RIG-I aim to put the immune system on high alert without triggering cold-like inflammation.
• Host-directed antivirals: Drugs that act on human entry or replication factors that viruses depend on, an approach validated by anti-PD-L1 antibodies in oncology.
• Physical barrier formulations: Nasal sprays, gels, and high-affinity viral-binding proteins (lectins, mucin domains, sialic acid-presenting glycoproteins) designed to capture viral particles before they enter the body.

Before 2020, broad-spectrum programs were sparse. The pandemic briefly flooded the field with capital and produced candidates such as pan-sarbecovirus vaccine prototypes, host-targeted small molecules, engineered interferons, and SARS-CoV-2 siRNAs. Many stalled once strain-specific COVID vaccines succeeded and funding thinned, but they left behind actionable signals for where to focus next.

The Numbers

• $500 million: Size of Intercept’s philanthropic commitment to catalyze BSP and ACT development.
• ~40: Scientists, pharma R&D leaders, biotech VCs, and regulators convened at the Stripe symposium.
• 15 to 25 days a year: Time the average healthy adult spends sick with a respiratory infection, about 5% of life.
• 12.8 billion infections in 2021: Global respiratory infection count, mostly viral.
• 65 million+ annually: Cases that progress to serious lower respiratory disease.
• ~7% of U.S. deaths from major causes: Share tied to respiratory infections.
• 9.8x asthma risk by age 6 in children infected with HRV between birth and age three in a high-risk cohort.
• 6.1x heart attack risk in the 7 days following influenza infection.
• 4.5 to 5x dementia risk after severe influenza.
• $600 billion, or ~0.6% of global GDP: Annual productivity drag from routine respiratory illness in non-pandemic years.
• 67% population protection: Threshold needed to approach elimination of a virus with R0 of 3.0.

What Comes Next

Intercept is now directing its $500M toward the technical gaps the symposium surfaced. That means funding the middle of the pipeline: cross-family vaccine platforms, durable nasal barriers, engineered interferons with cleaner side-effect profiles, and ACT deployment research in real buildings. The work also has explicit biodefense framing. Broad protection against respiratory pathogens is being treated as a first line of defense against both natural outbreaks and engineered biological threats, and the same products built to suppress seasonal colds and flu are expected to double as pandemic insurance.

What This Means for You

For business operators, the rising tide of capital behind respiratory-disease research signals that the infrastructure of indoor health may change. If Intercept’s bet pays off, the question for leaders could shift from “how do we handle cold and flu season” to “which broad-spectrum preventative do we offer as a benefit, and which air-cleaning retrofit pencils out for our office or storefront.” Downstream tooling, from at-home nasal sprays to far-UVC fixtures, may eventually look like other commoditizing infrastructure plays: pick the credible vendor, deploy early, and let the cost curve do its thing. For more analysis on how transformative tech initiatives reshape operations, browse our blog and stay current with the shifts that matter to SMB leaders.

For a closer look at how foundational tech shifts ripple into business tooling, see our coverage of the OpenAI Partner Network’s $150M enterprise push and our framework for prioritizing content in the AI search era. And if you want to explore more long-range tech and business analysis, head over to the BizScoreAI blog.

The Bigger Picture

A century ago, waterborne disease was treated as an unavoidable cost of being alive, until pharmaceutical advances and clean water infrastructure made cholera, typhoid, and dysentery rare. Intercept’s bet is that respiratory infections are the next category on that list, and that the missing ingredient has been patient funding for broad, cross-family solutions, not another strain-specific vaccine. Whether $500 million is enough to clear that bar is an open question, but the framing itself, that colds and flu are a solvable engineering problem, is the part worth holding onto.

Frequently Asked Questions